This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Is Aveanna Healthcare (AVAH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Aveanna Healthcare (AVAH) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Merit Medical Stock Gains 24.7% Year to Date: What's Behind the Rally?
by Zacks Equity Research
MMSI shows strong growth momentum with a robust product portfolio and recent acquisitions, positioning itself well in competitive healthcare markets.
Trinity Biotech Shares Surge on Positive Pre-Pivotal Clinical CGM Trial
by Zacks Equity Research
TRIB announces positive results from its pre-pivotal clinical European trial for a next-gen continuous glucose monitor, setting the stage for further development in 2025.
Here's Why You Should Retain CONMED Stock in Your Portfolio
by Zacks Equity Research
CNMD is poised for growth with strong product offerings and recurring revenues but faces headwinds from regulatory challenges, supply-chain constraints and cybersecurity risks.
Here's Why You Should Retain AMN HealthCare Stock in Your Portfolio
by Zacks Equity Research
AMN shows growth potential with its broad services and high demand but faces challenges from industry regulations and strong competition in the staffing space.
Inogen Stock Rises 47% in 6 Months: What's Driving the Rally?
by Zacks Equity Research
INGN shows impressive momentum, driven by strong sales growth, an expanding product portfolio and significant advancements in portable oxygen technology.
Glaukos Stock Soars 59.2% Year to Date: What's Behind the Rally?
by Zacks Equity Research
GKOS stock is being driven by strong product demand, international expansion and pipeline progress, which position it for long-term growth despite supply risks.
Here's Why You Should Add AngioDynamics Stock to Your Portfolio
by Zacks Equity Research
ANGO shows growth potential with its NanoKnife system and expanding U.S. sales but faces challenges from pricing pressure and macroeconomic factors.
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
by Zacks Equity Research
OPK's growth is fueled by Rayaldee's success and strategic partnerships. However, stiff competition and overdependence on its lead product are concerns.
Accelerate Diagnostics Stock Down Despite FDA Clearance for Arc System
by Zacks Equity Research
AXDX's Arc system gains FDA clearance, automating blood culture prep for faster microbial ID, improved sepsis outcomes and reduced hospital costs.
GE HealthCare Stock Likely to Rise After FDA Approval of Flyrcado
by Zacks Equity Research
GEHC's Flyrcado, a first-of-its-kind PET tracer for coronary artery disease, receives FDA approval, expanding diagnostic access and improving patient outcomes.
Axonics Shares Fall Despite Australia's Approval for R20 SNM Device
by Zacks Equity Research
AXNX's R20 rechargeable SNM system, offering long-lasting treatment for bladder and bowel dysfunction, gains approval in Australia.
DaVita Stock Rallies 17% in 3 Months: Is it Still Worth Buying?
by Indrajit Bandyopadhyay
DVA stock has the potential to continue its uptrend on the back of better revenues per treatment as well as growth of the overall dialysis market.
Aveanna Healthcare (AVAH) Is Up 2.41% in One Week: What You Should Know
by Zacks Equity Research
Does Aveanna Healthcare (AVAH) have what it takes to be a top stock pick for momentum investors? Let's find out.
MultiPlan Stock Falls Even After NRHA Rural Healthcare Deal
by Zacks Equity Research
MPLN and NRHA team up to empower rural healthcare providers with innovative technology and data-driven solutions, improving access, quality and affordability.
Tactile Medical Stock Rises After Positive Flexitouch Trial Results
by Zacks Equity Research
TCMD announces a new study evaluating Flexitouch. The study reveals significant improvements in health-related quality of life and clinical outcomes.
Fast-paced Momentum Stock Aveanna (AVAH) Is Still Trading at a Bargain
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Aveanna (AVAH) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
ICU Medical's Stock Rises Despite Bivona Tracheostomy Tube Recall
by Zacks Equity Research
ICUI's Smiths Medical recalls Bivona tracheostomy tubes over a defect that may lead to serious health risks, including airway loss and death.
Trinity Biotech's Stock Rises After Acquisition of Metabolomics
by Zacks Equity Research
TRIB acquires Metabolomics Diagnostics, expanding its platform with cutting-edge tech to enhance diagnostics in maternal health and diabetes management.
Cardinal Health Stock Likely to Gain From the Acquisition of ION
by Zacks Equity Research
CAH is set to acquire Oncology Network for $1.115 billion, expanding its oncology offerings while supporting community-based cancer care across 10 states.
ANGO Initiates RECOVER-AV Trial for AlphaVac F1885 in Europe
by Zacks Equity Research
AngioDynamics' RECOVER-AV trial evaluates the AlphaVac F1885 System's safety and efficacy in treating acute pulmonary embolism in Europe.
Here's Why You Should Hold Cencora Stock in Your Portfolio for Now
by Zacks Equity Research
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
GE HealthCare Shares Rise After AI-Powered Venue Sprint's Launch
by Zacks Equity Research
GEHC introduces Venue Sprint, a portable AI-enabled ultrasound device offering wireless probes, real-time insights and advanced clinical tools for improved care.
Is Aveanna Healthcare (AVAH) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aveanna Healthcare (AVAH) and AxoGen (AXGN) have performed compared to their sector so far this year.
BD Stock Rises as Neopak XtraFlow Syringe Expands in Biologics
by Zacks Equity Research
BDX launches the Neopak XtraFlow Glass Prefillable Syringe, enhancing drug delivery for biologics and expanding capacity with new high-volume production lines.